Episode 26. Management of Newly Diagnosed Hodgkin's Lymphoma
Blood Cancer Talks
00:00
The Impact of Echelon One on Practice Changes
S1826 was a phase three trial of almost a thousand patients with advanced stage Hodgkin lymphoma who were randomized to receive either six cycles of novolomab plus ABD or brentoxamabplus ABD. The primary endpoint of that study was progression free survival PFS. We just heard at the recent meetings this year that the one year progression free survival was 94% for the noVolomab ABD arm and 86% for BVABD so before we dive in if a patient sees you in clinic this week is that one year PFS result enough to shift your practice? Yeah that's a great question and usually I'm super conservative I'm waiting for it
Transcript
Play full episode
